Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis

The IL-23/IL-17 pathway is implicated in autoimmune diseases, particularly psoriasis, where biologics targeting IL-23 and IL-17 have shown significant clinical efficacy. Retinoid-related orphan nuclear receptor gamma t (RORγt) is required for Th17 differentiation and IL-17 production in adaptive and innate immune cells. We identified JNJ-54271074, a potent and highly-selective RORγt inverse agonist, which dose-dependently inhibited RORγt-driven transcription, decreased co-activator binding and promoted interaction with co-repressor protein. This compound selectively blocked Th17 differentiation, significantly reduced IL-17A production from memory T cells, and decreased IL-17A- and IL-22-producing human and murine γδ and NKT cells. In a murine collagen-induced arthritis model, JNJ-54271074 dose-dependently suppressed joint inflammation. Furthermore, JNJ-54271074 suppressed IL-17A production in human PBMC from rheumatoid arthritis patients. RORγt-deficient mice showed decreased IL-23-induced psoriasis-like skin inflammation and cytokine gene expression, consistent with dose-dependent inhibition in wild-type mice through oral dosing of JNJ-54271074. In a translational model of human psoriatic epidermal cells and skin-homing T cells, JNJ-54271074 selectively inhibited streptococcus extract-induced IL-17A and IL-17F. JNJ-54271074 is thus a potent, selective RORγt modulator with therapeutic potential in IL-23/IL-17 mediated autoimmune diseases.

[1]  Yuelei Shen,et al.  TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function , 2008, Nature.

[2]  L. Rogge,et al.  Proinflammatory Environment Dictates the IL-17–Producing Capacity of Human Invariant NKT Cells , 2011, The Journal of Immunology.

[3]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[4]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[5]  Yusuke Nakamura,et al.  A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility , 2010, Nature Genetics.

[6]  P. Griffin,et al.  Pharmacologic Repression of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γ Is Therapeutic in the Collagen‐Induced Arthritis Experimental Model , 2014, Arthritis & rheumatology.

[7]  R. Nurieva,et al.  Ursolic Acid Suppresses Interleukin-17 (IL-17) Production by Selectively Antagonizing the Function of RORγt Protein* , 2011, The Journal of Biological Chemistry.

[8]  B. Becher,et al.  RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. , 2009, Gastroenterology.

[9]  A. Bittner,et al.  Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation , 2014, Proceedings of the National Academy of Sciences.

[10]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[11]  P. Miossec,et al.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. , 1999, Arthritis and rheumatism.

[12]  M. Gazouli,et al.  NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease. , 2010, World journal of gastroenterology.

[13]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[14]  K. Papp,et al.  Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study , 2013, The British journal of dermatology.

[15]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[16]  A. Jetten.  Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism , 2009, Nuclear receptor signaling.

[17]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[18]  Mark S. Sundrud,et al.  Pharmacologic Inhibition of RORγt Regulates Th17 Signature Gene Expression and Suppresses Cutaneous Inflammation In Vivo , 2014, The Journal of Immunology.

[19]  D. Littman,et al.  Identification of IL-17-producing FOXP3+ regulatory T cells in humans , 2009, Proceedings of the National Academy of Sciences.

[20]  B. Elewski,et al.  Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review , 2016, American Journal of Clinical Dermatology.

[21]  A. Wolffe,et al.  Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. , 1999, Journal of molecular endocrinology.

[22]  Jeff P. Reeve,et al.  Association of interleukin-23 receptor variants with ankylosing spondylitis. , 2008, Arthritis and rheumatism.

[23]  A. Yoshimura,et al.  Foxp3 Inhibits RORγt-mediated IL-17A mRNA Transcription through Direct Interaction with RORγt*♦ , 2008, Journal of Biological Chemistry.

[24]  A. Bendele,et al.  Exacerbation of Collagen-Induced Arthritis by Oligoclonal, IL-17-Producing γδ T Cells1 , 2007, The Journal of Immunology.

[25]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[26]  Douglas J. Kojetin,et al.  Nuclear Receptors and Their Selective Pharmacologic Modulators , 2013, Pharmacological Reviews.

[27]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[28]  A. Pierani,et al.  Requirement for RORgamma in thymocyte survival and lymphoid organ development. , 2000, Science.

[29]  C. Dong.  Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells , 2006, Nature Reviews Immunology.

[30]  S. A. van de Pavert,et al.  Identification of natural RORγ ligands that regulate the development of lymphoid cells. , 2015, Cell metabolism.

[31]  B. Fauber,et al.  Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc). , 2014, Journal of medicinal chemistry.

[32]  P. Mease.  Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis , 2015, Current opinion in rheumatology.

[33]  M. Todaro,et al.  Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. , 2011, Blood.

[34]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[35]  J. Kelsen,et al.  Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells , 2016, Nature Medicine.

[36]  Sarah L. Gaffen,et al.  The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing , 2014, Nature Reviews Immunology.

[37]  E. Lubberts,et al.  Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. , 2011, Arthritis and rheumatism.

[38]  Richard W. Martin,et al.  A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis , 2013, Arthritis Research & Therapy.

[39]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[40]  A. Barton,et al.  The genetics of psoriatic arthritis: lessons from genome-wide association studies. , 2010, Discovery medicine.

[41]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[42]  Hergen Spits,et al.  Innate lymphoid cells: emerging insights in development, lineage relationships, and function. , 2012, Annual review of immunology.

[43]  S. Peternel,et al.  Immunopathogenesis of psoriasis: focus on natural killer T cells , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  A. Celada,et al.  Streptococcus induces circulating CLA(+) memory T-cell-dependent epidermal cell activation in psoriasis. , 2013, The Journal of investigative dermatology.

[45]  L. Stamp,et al.  Interleukin‐17: the missing link between T‐cell accumulation and effector cell actions in rheumatoid arthritis? , 2004, Immunology and cell biology.

[46]  D. Salinger,et al.  Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. , 2012, The Journal of investigative dermatology.

[47]  K. Pavelka,et al.  A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate , 2015, The Journal of Rheumatology.

[48]  Dušica Vidović,et al.  Suppression of TH17 Differentiation and Autoimmunity by a Synthetic ROR Ligand , 2011, Nature.

[49]  A. Blauvelt,et al.  This information is current as Hyperplasia Is Dependent on IL-17 A Mediated Psoriasis-Like Epidermal − IL-23 , 2010 .

[50]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[51]  B. Melegh,et al.  Functional variants of the interleukin-23 receptor gene in non-gastrointestinal autoimmune diseases. , 2009, Current medicinal chemistry.

[52]  A. Rachitskaya,et al.  Cutting Edge: NKT Cells Constitutively Express IL-23 Receptor and RORγt and Rapidly Produce IL-17 upon Receptor Ligation in an IL-6-Independent Fashion1 , 2008, The Journal of Immunology.

[53]  J. Farber,et al.  Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR61 , 2008, The Journal of Immunology.

[54]  C. Gordon,et al.  Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin , 2005, Arthritis research & therapy.

[55]  R. Kastelein,et al.  Understanding the IL-23-IL-17 immune pathway. , 2006, Trends in immunology.

[56]  B. Dema,et al.  IL23R: a susceptibility locus for celiac disease and multiple sclerosis? , 2008, Genes and Immunity.

[57]  Mark S. Sundrud,et al.  Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. , 2014, Immunity.

[58]  M. Genovese,et al.  Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. , 2014, The New England journal of medicine.

[59]  Patrick Durez,et al.  Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study , 2012, Annals of the rheumatic diseases.

[60]  M. Todaro,et al.  Differentiation, phenotype, and function ofinterleukin-17-producing human V{gamma}9V{delta}2 T cells , 2011 .

[61]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[62]  A. Bendele,et al.  Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. , 2007, Journal of immunology.

[63]  D. Getnet,et al.  Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity1 , 2009, The Journal of Immunology.

[64]  K. Mills,et al.  IL‐17‐producing γδ T cells and innate lymphoid cells , 2012, European journal of immunology.

[65]  R. Arbeit,et al.  Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation , 2013, PloS one.

[66]  Dan R. Littman,et al.  Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity , 2011, Nature.

[67]  P. Toogood,et al.  Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists. , 2015, Nature Chemical Biology.

[68]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[69]  Richard Bonneau,et al.  A Validated Regulatory Network for Th17 Cell Specification , 2012, Cell.

[70]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[71]  M. Genovese,et al.  A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors , 2014, Arthritis & rheumatology.

[72]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[73]  J. Sprent,et al.  IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival , 2014, Mucosal Immunology.